Insmed Stock Jumps 29% on Encouraging PAH Study Results

Key Takeaways TPIP reduced pulmonary vascular resistance by 35% and improved the six-minute walk distance by 35.5 meters. Insmed plans late-stage PAH trials in early 2026 after FDA talks on study design. TPIP also showed promise in PH-ILD, with plans for late-stage trials starting in H2 2025.Shares of Insmed (INSM) soared nearly 29% yesterday after the company reported positive top-line data from a phase IIb study evaluating its investigational treprostinil palmitil inhalation powder (TPIP) in patients wi ...